Litigation Details for ALCON PHARMACEUTICALS LTD. v. DR. REDDYS LABORATORIES, INC. (D.N.J. 2015)

ALCON PHARMACEUTICALS LTD. v. DR. REDDYS LABORATORIES, INC. (D.N.J. 2015)

Docket		Date Filed	2015-07-24
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	None	Referred To	Magistrate Judge Douglas E. Ar
Patents	6,284,804; 6,359,016; 9,402,805
Link to Docket	External link to docket

Details for ALCON PHARMACEUTICALS LTD. v. DR. REDDYS LABORATORIES, INC. (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-07-24	135		regarding U.S. Patent Nos. 6,284,804 (“the ’804 patent”), 6,359,016 (“the ’016 patent”) and 9,402,805…Joint Claim Construction regarding U.S. Patent Nos. 6,284,804, 6,359,016 and 9,402,805. Signed by Judge… recited in the preamble of claim 1 of the 6,284,804 patent is to be given its plain, ordinary and customary… The Patent Family The Patents-In-Suit include the ’804 patent, the ’016 patent and the …the ’805 patent. The ’016 patent is a continuation1 of the ’804 patent, and as such shares the same specification	External link to document
2015-07-24	67		AND ORDER Regarding Infringement re U.S. Patent Nos 6,284,804 and 6,359,016. Signed by Judge Peter G. …24 July 2015 3:15-cv-05756-PGS-DEA Patent None District Court, D. New Jersey	External link to document

Alcon Pharmaceuticals Ltd. v. Dr. Reddy’s Laboratories: Patent Litigation, Settlement, and Generic Entry Analysis

Last updated: August 9, 2026

Alcon Pharmaceuticals Ltd. sued Dr. Reddy’s Laboratories, Inc. in the U.S. District Court for the District of New Jersey after Dr. Reddy’s filed an ANDA seeking approval for a generic version of Pataday, Alcon’s olopatadine hydrochloride ophthalmic solution 0.2%. The case, No. 3:15-cv-05756-PGS-DE, centered on U.S. Patent No. 6,995,186. The dispute ended without a reported trial or merits judgment. The public docket indicates a negotiated resolution and case termination, leaving the patent’s validity and infringement questions undecided by the court.[1]

What drug and patent were involved in the Alcon v. Dr. Reddy’s case?

The litigation concerned olopatadine hydrochloride ophthalmic solution 0.2%, marketed by Alcon as Pataday.

Item	Detail
Brand	Pataday
Active ingredient	Olopatadine hydrochloride
Dosage form	Ophthalmic solution
Strength	0.2%
Therapeutic category	Ophthalmic antihistamine and mast-cell stabilizer
Reference listed drug	Pataday ophthalmic solution
Plaintiff	Alcon Pharmaceuticals Ltd.
Defendant	Dr. Reddy’s Laboratories, Inc.
Court	U.S. District Court for the District of New Jersey
Case number	3:15-cv-05756-PGS-DE
Primary patent	U.S. Patent No. 6,995,186
Filing year	2015

Pataday is indicated for the temporary prevention of itching of the eye associated with allergic conjunctivitis. The product uses olopatadine, a topical ophthalmic antihistamine with mast-cell stabilizing activity.[2]

U.S. Patent No. 6,995,186 is titled “Ophthalmic compositions containing olopatadine.” The patent covers ophthalmic formulations containing olopatadine and related formulation components. Its protection was directed to the branded product and the pharmaceutical composition rather than to olopatadine as a chemical entity.

What patents protect Pataday and olopatadine ophthalmic solution?

The central patent in the case was U.S. Patent No. 6,995,186, assigned to Alcon. The patent issued in February 2006 from an application claiming priority to an earlier filing associated with olopatadine ophthalmic formulations.[3]

The patent’s commercial importance came from its formulation claims. Olopatadine itself was known before the patent at issue. The asserted protection therefore focused on the composition and ophthalmic use of the product rather than on a new molecular entity.

U.S. Patent No. 6,995,186

Attribute	Information
Patent number	6,995,186
Title	Ophthalmic compositions containing olopatadine
Assignee	Alcon-related entity
Technology	Olopatadine ophthalmic formulations
Product relevance	Pataday 0.2% ophthalmic solution
Issue date	February 7, 2006
Statutory expiration	October 19, 2021, subject to applicable patent-term adjustments

The patent was listed in the FDA Orange Book for the relevant Pataday product. The Orange Book listing gave Alcon a statutory basis to bring a Hatch-Waxman infringement action after receiving Dr. Reddy’s Paragraph IV notice.[4]

Why did Alcon sue Dr. Reddy’s under Hatch-Waxman?

Dr. Reddy’s submitted an abbreviated new drug application for olopatadine hydrochloride ophthalmic solution 0.2%. The ANDA included a Paragraph IV certification asserting that the listed Alcon patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

A Paragraph IV certification is treated as an act of patent infringement under 35 U.S.C. § 271(e)(2). The branded manufacturer can sue within 45 days after receiving the certification. A timely suit generally triggers a statutory stay of FDA approval of the ANDA for up to 30 months, subject to court decisions and statutory exceptions.[5]

Alcon’s complaint alleged that Dr. Reddy’s proposed generic product would infringe the ’186 patent. The complaint sought the standard Hatch-Waxman remedies, including an order preventing FDA approval of the ANDA before patent expiration and other relief available under the patent laws.

The action did not arise from commercial sale of an infringing generic. It was an ANDA litigation proceeding based on the statutory submission of a proposed product.

What was the litigation timeline?

Date or period	Event
2001	Priority period associated with the olopatadine formulation patent family
February 7, 2006	U.S. Patent No. 6,995,186 issued
2015	Dr. Reddy’s submitted an ANDA and provided a Paragraph IV certification concerning Pataday
July 2015	Alcon filed the patent complaint in the District of New Jersey
2015 onward	Hatch-Waxman litigation proceeded before Judge Peter G. Sheridan, with magistrate-judge involvement
Before trial or merits judgment	Parties resolved the dispute and the case was terminated by stipulated dismissal
October 19, 2021	Listed patent reached its stated expiration date
2021-2022 period	Generic olopatadine 0.2% products became commercially available following the patent and regulatory barriers

The public docket does not report a claim-construction ruling, summary-judgment decision, trial verdict, or appellate decision. The case was therefore resolved through settlement rather than through a judicial determination of patent validity or infringement.[1]

What was the settlement outcome?

The settlement resolved the case without a public merits ruling. Public docket materials identify the dismissal, but the commercially important terms of the agreement, including any agreed generic launch date, royalty structure, authorized-generic provisions, or supply arrangements, were not set out in a publicly reported opinion.

That distinction matters. A stipulated dismissal establishes that the litigation ended. It does not establish that Dr. Reddy’s accepted the validity of the ’186 patent, that Alcon proved infringement, or that the patent would have survived a validity challenge.

The settlement likely allowed the parties to manage the timing and risk of generic entry without incurring the cost of full litigation. In pharmaceutical patent cases, such agreements often address:

• the earliest date on which the ANDA applicant may launch;
• whether the applicant can launch before patent expiration under specified conditions;
• allocation of litigation risk;
• commercial supply or authorized-generic rights;
• resolution of related claims involving the same ANDA.

No public source cited here establishes that Alcon granted Dr. Reddy’s a license, supplied an authorized generic, or paid a reverse-settlement payment. Those issues should not be inferred from the dismissal alone.

What was the Orange Book status of Pataday?

The Orange Book listed U.S. Patent No. 6,995,186 for the relevant Pataday formulation. The listing supported Alcon’s Hatch-Waxman action against Dr. Reddy’s.[4]

The product’s exclusivity profile was primarily patent-based:

Exclusivity category	Status
New chemical entity exclusivity	Not applicable to olopatadine ophthalmic solution
New clinical investigation exclusivity	Not the principal barrier identified in this case
Pediatric exclusivity	No case-specific extension identified in the public litigation record
Listed patent protection	U.S. Patent No. 6,995,186
Patent expiration	October 19, 2021
Biosimilar pathway	Not applicable
Generic pathway	ANDA under Hatch-Waxman

Olopatadine is a small-molecule active ingredient. Generic applicants use the ANDA pathway, not the biosimilar pathway under the Public Health Service Act.

When did Pataday lose exclusivity?

The key patent protection associated with this case expired on October 19, 2021. Generic entry risk therefore became substantially higher after that date, assuming the ANDA satisfied FDA requirements and no separate enforceable patent or regulatory exclusivity blocked approval.

Generic products containing olopatadine ophthalmic solution 0.2% became available in the period following expiration. The practical loss of exclusivity was not necessarily identical to the statutory patent expiration date because FDA approval timing, ANDA deficiencies, manufacturing readiness, and settlement provisions can affect commercial launch.

The settlement may have permitted an earlier launch date than the patent expiration date, but the public docket materials do not establish that term.

How strong was Alcon’s patent estate?

The estate was commercially meaningful but relatively concentrated in the litigation at issue. Alcon relied on a formulation patent tied directly to the 0.2% ophthalmic product. That type of patent can create a substantial barrier when the ANDA product falls within the asserted claims, but it is narrower than a broad composition-of-matter patent covering the active ingredient.

Strengths

• The patent was listed in the Orange Book.
• The patent was directly linked to the Pataday formulation.
• A Paragraph IV filing created an immediate statutory infringement claim.
• The lawsuit imposed a potential 30-month approval stay.
• The patent remained in force during the 2015 litigation.

Limitations

• Olopatadine was not a new chemical entity protected by a basic compound patent in this action.
• The asserted protection was formulation-focused.
• A formulation patent can face validity challenges based on prior art, obviousness, written description, and claim-construction disputes.
• The patent had a finite remaining term when the complaint was filed.
• The case ended without a court ruling confirming validity or infringement.

The litigation outcome provides no adjudicated measure of patent strength. Settlement can reflect litigation economics, launch timing, regulatory strategy, or commercial negotiation rather than a party’s assessment of the merits alone.

Did Dr. Reddy’s launch a generic Pataday product?

Dr. Reddy’s pursued an ANDA for olopatadine hydrochloride ophthalmic solution 0.2%. Generic olopatadine ophthalmic products later entered the U.S. market after the core patent protection ended or became commercially nonblocking.

The public record for this case does not establish that Dr. Reddy’s was the first generic entrant, that it launched under a specific settlement license, or that it received 180-day first-filer exclusivity. Those conclusions require a product-specific FDA approval and marketing record rather than the civil docket alone.

The commercial launch scenarios were:

1. Entry after October 19, 2021, following patent expiration.
2. Earlier entry under confidential or partially undisclosed settlement terms.
3. Delayed entry caused by FDA review, manufacturing readiness, or ANDA deficiencies.
4. Entry after resolution of separate patent or regulatory issues not litigated in this case.

What litigation risks affected generic entry?

The principal risk for Dr. Reddy’s was an injunction or delayed FDA approval based on infringement of the ’186 patent. The principal risk for Alcon was an adverse invalidity or non-infringement ruling that could have opened the market before the patent’s scheduled expiration.

The case also carried settlement-related risks:

• A confidential launch date could affect market share and price erosion.
• Multiple ANDA applicants could create overlapping challenges.
• A first generic entrant could gain a commercial advantage even without 180-day exclusivity.
• Formulation patents could be designed around through changes to inactive ingredients or concentration.
• FDA approval of a therapeutically equivalent product could accelerate substitution through pharmacy channels.

Because no merits decision was issued, the case did not create binding precedent for other olopatadine manufacturers.

Which companies challenged or competed with Pataday?

The competitive field included manufacturers pursuing generic olopatadine ophthalmic solutions and branded ophthalmic allergy products. Relevant commercial competitors included:

• Dr. Reddy’s Laboratories;
• Apotex;
• Sandoz and other generic manufacturers;
• Bausch + Lomb;
• Alcon’s own branded and over-the-counter Pataday products;
• competing ophthalmic allergy products containing ketotifen or other antihistamine agents.

Generic competition was more relevant than biosimilar competition. Biosimilar risk was zero for this small-molecule ophthalmic product because the FDA regulatory pathway was an ANDA.

What was the revenue exposure for Alcon?

Alcon does not generally report Pataday revenue as a separately disclosed line item in its principal public financial statements. The company reports broader ophthalmic pharmaceutical and vision-care results rather than case-specific revenue exposure.

The commercial impact of generic entry depended on:

• Pataday prescription and over-the-counter sales;
• the shift from prescription Pataday to OTC products;
• the number of approved generic competitors;
• retail substitution rates;
• pricing and rebate changes;
• Alcon’s ability to retain consumers through brand recognition and product differentiation.

The litigation concerned a single ophthalmic product formulation. It did not threaten Alcon’s broader pharmaceutical portfolio, surgical franchise, contact-lens business, or medical-device operations.

What is the current legal status of the case?

The case is closed. The parties resolved the dispute without a reported trial judgment or appellate ruling. The docket does not establish a finding that the ’186 patent was valid, infringed, or enforceable.

The patent itself reached its listed expiration date in 2021. The case therefore has limited continuing value as a direct barrier to generic olopatadine entry. Its principal business significance lies in the settlement structure, Paragraph IV strategy, and use of a formulation patent to delay or negotiate generic competition.

Key Takeaways

• The case involved Pataday, an olopatadine hydrochloride ophthalmic solution 0.2%.
• Alcon asserted U.S. Patent No. 6,995,186.
• Dr. Reddy’s challenged the patent through an ANDA Paragraph IV certification.
• Alcon filed the case in 2015 in the District of New Jersey.
• The case ended by negotiated dismissal without a merits ruling.
• The public record does not disclose the material commercial terms of the settlement.
• The ’186 patent expired on October 19, 2021.
• Generic entry risk increased materially after that date.
• The dispute involved small-molecule generic competition, not biosimilar competition.
• The patent estate was formulation-focused and lacked an adjudicated validity or infringement result.

FAQs About Alcon v. Dr. Reddy’s and Pataday

Did Alcon win the case against Dr. Reddy’s?

No merits victory was entered. The case ended through settlement and stipulated dismissal, so the court did not decide whether the patent was valid or infringed.

What was Dr. Reddy’s Paragraph IV challenge directed to?

The challenge was directed to U.S. Patent No. 6,995,186, which covered olopatadine ophthalmic formulations associated with Pataday 0.2%.

Was Pataday protected by a biologic exclusivity period?

No. Pataday contains olopatadine, a small-molecule drug. Its generic pathway was an ANDA, not a biosimilar application.

Could Dr. Reddy’s have launched before the patent expired?

Possibly, depending on the settlement terms. The public docket does not disclose a confirmed launch date or license provision.

Does the case establish that Pataday’s formulation patent was enforceable?

No. The absence of a merits ruling means the case does not establish enforceability, validity, infringement, or claim scope as a matter of precedent.

References

1. U.S. District Court for the District of New Jersey. (2015). Alcon Pharmaceuticals Ltd. v. Dr. Reddy’s Laboratories, Inc., No. 3:15-cv-05756-PGS-DE. PACER/Court docket.

2. U.S. Food and Drug Administration. (n.d.). Pataday ophthalmic solution, olopatadine hydrochloride 0.2% prescribing information. FDA.

3. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 6,995,186: Ophthalmic compositions containing olopatadine. Patent Center.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

5. Hatch-Waxman Amendments, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).